Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 3, 2014, Pages 339-344

  Wakerley, Benjamin R ^a   Yuki, Nobuhiro ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GT1A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

AREFLEXIA; ARM WEAKNESS; CLINICAL FEATURE; DEMYELINATING DISEASE; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; GUILLAIN BARRE SYNDROME; HUMAN; MUSCLE WEAKNESS; NERVE CONDUCTION; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHARYNGEAL CERVICAL BRACHIAL VARIANT OF GUILLAIN BARRE SYNDROME; PRIORITY JOURNAL; REVIEW;

GANGLIOSIDE; GUILLAIN-BARRE SYNDROME; NEUROPATHY;

AUTOANTIBODIES; BRACHIAL PLEXUS NEUROPATHIES; DIAGNOSIS, DIFFERENTIAL; GANGLIOSIDES; GUILLAIN-BARRE SYNDROME; HUMANS; MUSCLE WEAKNESS; NECK; NECK MUSCLES; PHARYNGEAL DISEASES;

EID: 84896727343     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-305397     Document Type: Review

References (34)

1. Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol 1986;43:1150-2. (Pubitemid 17174443)
2. Nagashima T, Koga M, Odaka M, et al. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol 2007;64:1519-23. (Pubitemid 47572676)
3. Ropper AH. Further regional variants of acute immune polyneuropathy: bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol 1994;51:671-5. (Pubitemid 24201885)
4. Arai M, Susuki K, Koga M. Axonal pharyngeal-cervical-brachial variant of Guillain-Barré syndrome without anti-GT1a IgG antibody. Muscle Nerve 2003;28:246-50. (Pubitemid 36927811)
5. Chan YC, Ahmad A, Paliwal P, et al. Non-demyelinating, reversible conduction failure in a case of pharyngeal-cervical-brachial weakness overlapped by Fisher syndrome. J Neurol Sci 2012;321:103-6.
6. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré Syndrome. Philadelphia: FA Davus, 1991.
7. Yuki N, Kokubun N, Kuwabara S, et al. Guillain-Barré syndrome associated with normal or exaggerated tendon reflexes. J Neurol 2012;259:1181-90.
8. Miura Y, Susuki K, Yuki N, et al. Guillain-Barré syndrome presenting pharyngealcervical-brachial weakness in the recovery phase. Eur Neurol 2002;48:53-4.
9. Mizoguchi K, Hase A, Obi T, et al. Two species of antiganglioside antibodies in a patient with a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1994;57:1121-3.
10. Kashihara K, Shiro Y, Koga M, et al. IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1998;65:799. (Pubitemid 28486671)
11. Osaki Y, Koga M, Matsubayashi K, et al. Asymmetric pharyngeal-cervical- brachial weakness associated with anti-GT1a IgG antibody. Acta Neurol Scand 2002;106:234-5.
12. Okuda B, Koga M, Katsuta T, et al. Fulminant Guillain-Barré syndrome after Campylobacter jejuni enteritis and monospecific anti-GT1a IgG antibody. Intern Med 2002;41:889-91. (Pubitemid 35314796)
13. Pan CL, Shun CT, Susuki K, et al. Pharyngeal-brachial palsy after cytomegalovirus colitis. Neurology 2004;62:153-4. (Pubitemid 38082897)
14. Capasso M, Notturno F, Manzoli C, et al. Reversible conduction failure in pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Muscle Nerve 2010;42:608-12.
15. Ito M, Matsuno K, Sakumoto Y, et al. Ataxic Guillain-Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J Neurol Neurosurg Psychiatry 2011;82:294-9.
16. Onodera M, Mori M, Koga M, et al. Acute isolated bulbar palsy with anti-GT1a IgG antibody subsequent to Campylobacter jejuni enteritis. J Neurol Sci 2002;205:83-4. (Pubitemid 36158998)
17. O'Leary CP, Veitch J, Durward WF, et al. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J Neurol Neurosurg Psychiatry 1996;61:649-51. (Pubitemid 27023349)
18. Numata Y, Uematsu M, Hino-Fukuyo N, et al. Case of a pharyngeal-cervical- brachial variant of Guillain-Barré syndrome without pharyngeal palsy. No To Hattatsu 2011;43:482-5.
19. Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000;48:624-31.
20. Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-17. (Pubitemid 23318855)
21. Yuki N, Yoshino H, Sato S, et al. Severe acute axonal form of Guillain-Barré syndrome associated with IgG anti-GD1a antibodies. Muscle Nerve 1992;15:899-903.
22. Koga M, Yoshino H, Morimatsu M, et al. Anti-GT1a IgG in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2002;72:767-71.
23. Yowler BC, Schengrund CL. Glycosphingolipids-sweets for botulinum neurotoxin. Glycoconj J 2004;21:287-93.
24. Kitamura M, Iwamori M, Nagai Y. Interaction between Clostridium botulinum neurotoxin and gangliosides. Biochim Biophys Acta 1980;628:328-35. (Pubitemid 10119130)
25. Kamata Y, Kozaki S, Sakaguchi G, et al. Evidence for direct binding of Clostridium botulinum type E derivative toxin and its fragments to gangliosides and free fatty acids. Biochem Biophys Res Commun 1986;140:1015-19. (Pubitemid 17207792)
26. Kimoto K, Koga M, Odaka M, et al. Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology 2006;67:1837-43. (Pubitemid 44900763)
27. Susuki K, Rasband MN, Tohyama K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27:3956-67. (Pubitemid 46597169)
28. McGonigal R, Rowan EG, Greenshields KN, et al. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 2010;133:1944-60.
29. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011;29:599-612.
30. Nishimoto Y, Odaka M, Hirata K, et al. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol 2004;148:200-5. (Pubitemid 38232656)
31. Padua L, Aprile I, Monaco ML, et al. Neurophysiological assessment in the diagnosis of botulism: usefulness of single-fiber EMG. Muscle Nerve 1999;22:1388-92. (Pubitemid 29468423)
32. Kuwabara S, Kokubun N, Misawa S, et al. Neuromuscular transmission is not impaired in axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2011;82:1174-7.
33. Kuwabara S, Misawa S, Takahashi H, et al. Anti-GQ1b antibody does not affect neuromuscular transmission in human limb muscle. J Neuroimmunol 2007;189:158-62. (Pubitemid 47379432)
34. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012;366: 2294-304.